ARSENIC TRIOXIDE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal	ARSENIC TRIOXIDE	arsenic trioxide	INJECTABLE;INJECTION	210739	ANDA	Amneal Pharmaceuticals LLC	70121-1483-7	10 VIAL, SINGLE-DOSE in 1 CARTON (70121-1483-7) / 10 mL in 1 VIAL, SINGLE-DOSE (70121-1483-1)	2021-01-25
Amneal	ARSENIC TRIOXIDE	arsenic trioxide	INJECTABLE;INJECTION	210739	ANDA	Amneal Pharmaceuticals LLC	70121-1658-1	10 VIAL, SINGLE-DOSE in 1 CARTON (70121-1658-1) / 6 mL in 1 VIAL, SINGLE-DOSE (70121-1658-6)	2021-08-20
Amring Pharms	ARSENIC TRIOXIDE	arsenic trioxide	INJECTABLE;INJECTION	210802	ANDA	Nordic Pharma, Inc.	69918-720-10	10 VIAL, GLASS in 1 CARTON (69918-720-10) / 10 mL in 1 VIAL, GLASS (69918-720-01)	2018-11-14
Eugia Pharma	ARSENIC TRIOXIDE	arsenic trioxide	INJECTABLE;INJECTION	214011	ANDA	Eugia US LLC	55150-366-10	10 CARTON in 1 CARTON (55150-366-10) / 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-366-01) / 6 mL in 1 VIAL, SINGLE-DOSE	2021-10-15
Fresenius Kabi Usa	ARSENIC TRIOXIDE	arsenic trioxide	INJECTABLE;INJECTION	208231	ANDA	Fresenius Kabi USA, LLC	63323-637-10	10 VIAL, SINGLE-DOSE in 1 CARTON (63323-637-10) / 10 mL in 1 VIAL, SINGLE-DOSE (63323-637-03)	2018-08-31
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Arsenic trioxide is a critical active pharmaceutical ingredient (API) used in the treatment of certain hematological malignancies, notably acute promyelocytic leukemia (APL). Its procurement requires suppliers with stringent quality control, regulatory compliance, and secure supply chain management. This analysis identifies key suppliers and assesses critical factors for pharmaceutical manufacturers.

What is the Current Global Supply Landscape for Pharmaceutical-Grade Arsenic Trioxide?

The global supply of pharmaceutical-grade arsenic trioxide is concentrated among a limited number of specialized manufacturers. These entities must adhere to Good Manufacturing Practices (GMP) and possess certifications relevant to pharmaceutical production, such as those issued by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The regulatory hurdles for API production, particularly for compounds with a history of toxicity, are substantial, limiting the number of qualified suppliers.

Key aspects of the supply landscape include:

Limited Manufacturer Base: Production is not widespread. Manufacturers often specialize in high-purity inorganic chemicals with pharmaceutical applications.
Regulatory Rigor: Suppliers must demonstrate adherence to strict quality standards, including impurity profiling, stability testing, and batch-to-batch consistency.
Geographic Distribution: While production may occur in various regions, the distribution network often involves specialized distributors capable of handling hazardous materials and meeting pharmaceutical supply chain demands.
Pricing Dynamics: Pricing is influenced by production costs, regulatory compliance overhead, volume of purchase, and market demand. The specialized nature of the API and its niche application contribute to a premium price point.

Who are the Primary Suppliers of Arsenic Trioxide for Pharmaceutical Use?

The primary suppliers are typically chemical manufacturers with established pharmaceutical-grade production capabilities. These companies often produce other inorganic APIs and fine chemicals.

IOL Chemicals and Pharmaceuticals Ltd. (India): IOLCP is a significant player in the API market. While they produce a wide range of APIs, their regulatory filings and product portfolios indicate the capacity for pharmaceutical-grade inorganic compounds. They have extensive experience with GMP manufacturing and international regulatory standards.
Merck KGaA (Germany): Through its Life Science business sector, Merck KGaA (operating as MilliporeSigma in the U.S. and Canada) offers a broad catalog of high-purity chemicals. Their production facilities are geared towards pharmaceutical and research applications, requiring strict quality control and documentation. They supply arsenic trioxide in various grades, including those suitable for API synthesis and research.
Alfa Aesar, part of Thermo Fisher Scientific (U.S.): Alfa Aesar is a well-known supplier of research chemicals, metals, and materials. They offer arsenic trioxide in high-purity grades. While often associated with research quantities, their broader supply chain and manufacturing standards can extend to bulk pharmaceutical needs, contingent on specific regulatory qualifications and customer requirements.
Strem Chemicals, Inc. (U.S.): Strem Chemicals specializes in high-purity specialty chemicals. Their product lines include inorganic compounds produced under rigorous quality control systems, suitable for pharmaceutical R&D and potential API manufacturing.

It is crucial for pharmaceutical manufacturers to conduct thorough due diligence on any potential supplier, including on-site audits, verification of regulatory certifications, and independent testing of product batches.

What are the Critical Quality Attributes and Regulatory Requirements for Pharmaceutical Arsenic Trioxide?

Pharmaceutical-grade arsenic trioxide must meet stringent quality attributes and comply with global regulatory standards to ensure patient safety and efficacy.

Critical Quality Attributes (CQAs):

Purity: Typically defined as ≥ 99.0% arsenic trioxide (As₂O₃). Impurities must be identified, quantified, and controlled within specified limits. Common impurities can include other arsenic oxides, heavy metals, and residual solvents.
Identity: Confirmed through spectroscopic methods (e.g., Infrared Spectroscopy, X-ray Diffraction) and wet chemistry analyses.
Assay: The quantitative determination of arsenic trioxide content, usually by titration or instrumental analysis (e.g., Inductively Coupled Plasma Mass Spectrometry - ICP-MS).
Particle Size Distribution: Critical for dissolution rates and formulation homogeneity, especially in solid dosage forms or suspensions. Specifications are often defined by sieve analysis or laser diffraction.
Heavy Metals: Limits for metals such as lead (Pb), cadmium (Cd), mercury (Hg), and arsenic itself (if present as free inorganic arsenic or other species) are extremely low, often in the parts-per-million (ppm) range.
Residual Solvents: If used in the manufacturing process, residual solvents must be controlled according to ICH Q3C guidelines.
Water Content: Determined by Karl Fischer titration, as excessive moisture can affect stability and reactivity.

Regulatory Requirements:

Good Manufacturing Practices (GMP): Suppliers must operate under cGMP regulations as defined by agencies like the FDA (21 CFR Part 210/211), EMA, and WHO. This encompasses all aspects of production, including personnel, facilities, equipment, documentation, and quality control.
Drug Master Files (DMFs): Suppliers often submit DMFs to regulatory agencies. These confidential documents detail the manufacturing process, quality control procedures, and stability data for the API. Pharmaceutical companies can reference these DMFs in their drug applications.
Pharmacopoeial Standards: Arsenic Trioxide must comply with specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define testing methods and acceptance criteria for identity, purity, assay, and other critical attributes.
REACH and CLP Regulations (EU): For suppliers operating within or exporting to the European Union, compliance with Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) and Classification, Labelling and Packaging (CLP) regulations is mandatory due to the hazardous nature of arsenic compounds.
Export/Import Controls: Due to its potential misuse, arsenic trioxide may be subject to specific export and import controls in various countries.

What are the Supply Chain and Logistics Considerations for Arsenic Trioxide?

The supply chain and logistics for arsenic trioxide are complex due to its hazardous nature, regulatory oversight, and the need for strict quality preservation.

Key Considerations:

Hazardous Material Classification: Arsenic trioxide is classified as a highly toxic substance. This necessitates specialized packaging, labeling, handling, transportation, and storage protocols compliant with international dangerous goods regulations (e.g., UN Recommendations on the Transport of Dangerous Goods, IATA for air freight, IMDG for sea freight, ADR for road transport in Europe).
Temperature and Humidity Control: While arsenic trioxide is relatively stable, maintaining controlled environmental conditions during transit and storage can prevent degradation and moisture absorption, preserving API integrity.
Security: Due to its toxicity, robust security measures are required throughout the supply chain to prevent diversion or tampering. This includes secure warehousing, chain of custody protocols, and background checks for personnel involved.
Lead Times and Inventory Management: The limited number of manufacturers and specialized logistics can lead to longer lead times. Pharmaceutical companies must carefully manage inventory levels to ensure uninterrupted production, balancing the risk of stock-outs against the costs of holding excess hazardous inventory.
Customs and Import/Export Compliance: Navigating customs regulations for hazardous and controlled substances across different jurisdictions is critical. Proper documentation, permits, and adherence to import/export licenses are essential to avoid delays and penalties.
Waste Disposal: The disposal of any waste generated during manufacturing, packaging, or transport must comply with stringent environmental regulations for hazardous waste.
Supplier Qualification and Auditing: Rigorous supplier qualification processes are paramount. This involves not only assessing manufacturing capabilities and quality systems but also evaluating their logistical expertise and compliance with hazardous material handling regulations. Regular audits are necessary to ensure ongoing compliance.

How do Arsenic Trioxide Suppliers Ensure Traceability and Prevent Counterfeiting?

Ensuring traceability and preventing counterfeiting in the pharmaceutical supply chain for arsenic trioxide involves a multi-faceted approach combining regulatory compliance, technological solutions, and robust internal processes.

Methods Employed by Suppliers:

Batch Manufacturing Records (BMRs): Comprehensive BMRs are maintained for each production lot. These records document every step of the manufacturing process, from raw material receipt to final API packaging, including details of equipment used, operators involved, in-process controls, and testing results.
Unique Batch Identification: Each batch of arsenic trioxide is assigned a unique lot or batch number. This number is affixed to all packaging and is cross-referenced in all documentation.
Certificates of Analysis (CoA): A CoA is issued for each batch, detailing the specific test results against the established specifications and pharmacopoeial standards. This document is a primary tool for verifying product quality and identity.
Serialized Packaging: Modern supply chains increasingly employ serialization, where individual saleable units (e.g., drums or containers of API) are assigned a unique serial number that is logged into a database. This allows for end-to-end tracking from the manufacturer to the end-user.
Secure Packaging and Tamper-Evident Seals: Packaging materials are chosen to protect the API and are designed to show clear evidence of tampering if breached. Tamper-evident seals are applied to containers.
Supplier Audits and Verifications: Pharmaceutical companies conduct regular audits of their arsenic trioxide suppliers to verify GMP compliance, quality control systems, and the integrity of their traceability procedures.
Regulatory Filings (DMFs): Drug Master Files submitted to regulatory authorities contain detailed information about the API’s manufacturing and quality control, which regulators use to assess the supplier's reliability and compliance.
Industry Standards and Best Practices: Adherence to industry standards such as those set by the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides a framework for robust quality and traceability systems.
Blockchain Technology (Emerging): While not yet widespread for this specific API, blockchain technology offers the potential for immutable, transparent, and verifiable records of a product’s journey through the supply chain, significantly enhancing traceability and combating counterfeiting.

Key Takeaways

The pharmaceutical arsenic trioxide market is characterized by a limited number of specialized GMP-compliant suppliers due to significant regulatory and manufacturing hurdles.
Key suppliers include IOL Chemicals and Pharmaceuticals Ltd., Merck KGaA, Alfa Aesar (Thermo Fisher Scientific), and Strem Chemicals, Inc., with extensive due diligence required by procuring companies.
Critical quality attributes for pharmaceutical arsenic trioxide include high purity (≥ 99.0%), controlled impurity profiles, and adherence to pharmacopoeial standards (USP, Ph. Eur., JP).
Regulatory compliance, particularly cGMP, DMF submissions, and pharmacopoeial monographs, is non-negotiable for suppliers.
Supply chain and logistics demand specialized handling due to the hazardous nature of arsenic trioxide, requiring adherence to dangerous goods regulations, secure transportation, and careful inventory management.
Traceability and anti-counterfeiting measures rely on comprehensive batch records, unique identification, Certificates of Analysis, serialized packaging, and rigorous supplier verification processes.

Frequently Asked Questions

Are there any single-source risks associated with arsenic trioxide supply? The limited number of qualified suppliers can present single-source risks. Pharmaceutical companies mitigate this by qualifying multiple suppliers where feasible, maintaining safety stock, and engaging in long-term supply agreements.
What is the typical lead time for obtaining pharmaceutical-grade arsenic trioxide? Lead times can vary significantly but often range from 8 to 16 weeks due to specialized manufacturing processes, quality control testing, and complex logistics for hazardous materials.
Can research-grade arsenic trioxide be used for pharmaceutical manufacturing? No. Research-grade arsenic trioxide typically does not meet the stringent purity, impurity profile, and GMP manufacturing requirements necessary for pharmaceutical API use and cannot be substituted without extensive re-validation and regulatory approval.
What is the role of the USP/NF and Ph. Eur. monographs in supplier selection? These monographs define the official standards for arsenic trioxide intended for pharmaceutical use. Suppliers must demonstrate that their product consistently meets all specified tests and limits within these monographs.
How does geopolitical instability affect the supply of arsenic trioxide? Geopolitical events can disrupt raw material sourcing, manufacturing operations, and transportation routes for any chemical, including arsenic trioxide. Suppliers with diversified manufacturing footprints and robust risk management strategies are better positioned to maintain supply continuity.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-regulation/current-good-manufacturing-practice-cgmp-regulations [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/good-manufacturing-practice [3] United States Pharmacopeial Convention. (n.d.). USP-NF. Retrieved from https://www.usp.org/products/usp-nf [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia [5] United Nations. (n.d.). Recommendations on the Transport of Dangerous Goods - Model Regulations. Retrieved from https://www.unece.org/transport/dangerous-goods.html [6] International Air Transport Association. (n.d.). Dangerous Goods Regulations. Retrieved from https://www.iata.org/en/publications/dgr/ [7] International Maritime Organization. (n.d.). IMDG Code. Retrieved from https://www.imo.org/en/OurWork/Safety/Pages/DangerousGoods.aspx [8] United Nations Economic Commission for Europe. (n.d.). ADR. Retrieved from https://unece.org/transport/dangerous-goods/adr-agreement-concerned-0 [9] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/ [10] REACH Regulation (EC) No 1907/2006. (n.d.). EUR-Lex. Retrieved from https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02006R1907-2023-05-01 [11] CLP Regulation (EC) No 1272/2008. (n.d.). EUR-Lex. Retrieved from https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02008R1272-2023-05-01

Suppliers and packagers for generic pharmaceutical drug: ARSENIC TRIOXIDE